A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Phase of Trial: Phase III
Latest Information Update: 16 Dec 2017
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 02 May 2017 Planned number of patients changed from 3155 to 2980.
- 02 May 2017 Planned End Date changed from 1 Oct 2018 to 7 Apr 2019.
- 02 May 2017 Planned primary completion date changed from 1 Oct 2018 to 7 Apr 2019.